Benitec Biopharma Inc. Total Liabilities and Equity
Benitec Biopharma Inc. (BNTC) had Total Liabilities and Equity of $182.62 million as of 2026-06-30, per its 10-K filed 2026-09-14.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-09-14
- 2026-06-30: Liabilities and Equity $182.62M.
- 2026-03-31: Liabilities and Equity $187.00M.
- 2025-12-31: Liabilities and Equity $190.68M.
- 2025-09-30: Liabilities and Equity $96.03M.
| Period end | Liabilities and Equity |
|---|---|
| 2026-06-30 | $182.62M 10-K · filed 2026-09-14 |
| 2026-03-31 | $187.00M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $190.68M 10-Q · filed 2026-02-12 |
| 2025-09-30 | $96.03M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $99.59M 10-K · filed 2026-09-14 |
| 2025-03-31 | $105.21M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $79.07M 10-Q · filed 2025-02-14 |
| 2024-09-30 | $68.77M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $52.21M 10-K/A · filed 2026-03-20 |
| 2024-03-31 | $15.00M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $21.35M 10-Q · filed 2024-02-13 |
| 2023-09-30 | $27.05M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $4.46M 10-K · filed 2024-09-26 |
| 2023-03-31 | $8.22M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $11.90M 10-Q · filed 2023-02-13 |
| 2022-09-30 | $18.11M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $5.97M 10-K · filed 2023-09-21 |
| 2022-03-31 | $10.06M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $14.01M 10-Q · filed 2022-02-14 |
| 2021-09-30 | $17.84M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $21.38M 10-K · filed 2022-09-02 |
| 2021-03-31 | $13.43M 10-Q · filed 2021-05-12 |
| 2020-12-31 | $15.51M 10-Q · filed 2021-02-09 |
| 2020-09-30 | $8.92M 10-Q · filed 2020-11-13 |
| 2020-06-30 | $11.59M 10-K · filed 2021-09-20 |
| 2019-06-30 | $19.23M 10-K · filed 2020-09-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |